Lista de obras -

<sup>18</sup>F-FDG PET maximum intensity projections and artificial intelligence: a win-win combination to easily measure prognostic biomarkers in DLBCL patients

artículo científico publicado en 2022

A tumor volume and performance status model to predict outcome prior to treatment in diffuse large B-cell lymphoma

artículo científico publicado en 2022

An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax.

artículo científico publicado en 2013

Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies.

artículo científico publicado en 2016

FDG-PET in PMBCL: which heterogeneity?

artículo científico publicado en 2018

High total metabolic tumor volume at baseline predicts survival independent of response to therapy

scientific article published on 01 April 2020

Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and G

artículo científico

PET-guided clinical trials in Hodgkin lymphoma: to agree or not to agree, that is the reviewer's question

artículo científico publicado en 2017

Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma

artículo científico publicado en 2014

Prognostic model for high tumor burden follicular lymphoma integrating baseline and end induction PET: a LYSA/FIL study.

artículo científico publicado en 2018

Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project

artículo científico publicado en 2019

Quantitative FDG-PET: a new biomarker in PMBCL.

artículo científico publicado en 2015

Reply to H.J.A. Adams et al and E. Laffon et al

scientific article published on 28 December 2016

Reply to J. Wang et al

scientific article published on 12 February 2019

Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report